<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7202545\results\search\disease\results.xml">
  <result pre="Research Perspective Geroprotective and senoremediative strategies to reduce the comorbidity," exact="infection" post="rates, severity, and lethality in gerophilic and gerolavic infections"/>
  <result pre="comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic" exact="infections" post="ZhavoronkovAlex12[1], [2], Correspondence to: Alex Zhavoronkov; email: alex@insilico.com collection:"/>
  <result pre="pandemic has uncovered the age-associated vulnerability in the burden of" exact="disease" post="and put aging research in the spotlight. The limited"/>
  <result pre="of disease and put aging research in the spotlight. The" exact="limited" post="data available indicates that COVID-19 should be referred to"/>
  <result pre="a gerolavic (from Greek, gÃ©ros â€œold manâ€� and epilavÃ­s, â€œharmfulâ€�)" exact="infection" post="because the infection rates, severity, and lethality are substantially"/>
  <result pre="Greek, gÃ©ros â€œold manâ€� and epilavÃ­s, â€œharmfulâ€�) infection because the" exact="infection" post="rates, severity, and lethality are substantially higher in the"/>
  <result pre="vaccination response, as well as the severity and lethality of" exact="infectious diseases." post="While vaccination reduces infection rates, and therapeutic interventions reduce"/>
  <result pre="the severity and lethality of infectious diseases. While vaccination reduces" exact="infection" post="rates, and therapeutic interventions reduce the severity and lethality"/>
  <result pre="sirolimus (rapamycin) and its close derivative rapalog everolimus (RAD001), decreased" exact="infection" post="rates in a small sample of elderly patients. This"/>
  <result pre="of elderly patients. This article presents a review of the" exact="limited" post="literature available on geroprotective and senoremediative interventions that may"/>
  <result pre="and senoremediative interventions that may be investigated to decrease the" exact="disease" post="burden of gerolavic infections. This article also highlights a"/>
  <result pre="[1] that leads to loss of function and is the" exact="primary" post="risk factor for major human pathologies including cancer, diabetes,"/>
  <result pre="primary risk factor for major human pathologies including cancer, diabetes," exact="cardiovascular" post="disorders, and neurodegenerative diseases [1, 2]. Although there is"/>
  <result pre="community, proposals have been made to classify aging as a" exact="disease" post="in order to develop therapeutic strategies to prevent or"/>
  <result pre="commonly referred to as age-related [6]. Many pathogens are more" exact="infectious" post="and prevalent in the elderly, [7â€&quot;10] and may be"/>
  <result pre="gÃ©ros â€œold manâ€�, and epilavÃ­s, â€œharmfulâ€�) may more appropriately describe" exact="infections" post="that cause the most harm in the elderly. COVID-19"/>
  <result pre="harm in the elderly. COVID-19 is a gerophilic and gerolavic" exact="infection" post="Statistics from the COVID-19 pandemic indicate that COVID-19 is"/>
  <result pre="World in Data [16] and The Lancetâ€™s Global Burden of" exact="Disease" post="[17] provide deep visual insight into the global burden"/>
  <result pre="and The Lancetâ€™s Global Burden of Disease [17] provide deep" exact="visual" post="insight into the global burden of disease by cause"/>
  <result pre="[17] provide deep visual insight into the global burden of" exact="disease" post="by cause and demographics. In 2017, there were 56"/>
  <result pre="age 89. According to estimates by the US Centers for" exact="Disease" post="Control [19], approximately 5,945,690 individuals older than 65 had"/>
  <result pre="Disease Control [19], approximately 5,945,690 individuals older than 65 had" exact="symptomatic" post="influenza during the 2017-2018 season, resulting in 3,329,586 medical"/>
  <result pre="of the possible causes of the age-associated increases in COVID-19" exact="infection" post="rate, severity, and lethality is immunosenescence. Immunosenescence is a"/>
  <result pre="a well-known age-related process contributing to the global burden of" exact="disease" post="[21]. It is among the major factors underlying the"/>
  <result pre="in the response rate to vaccinations and the virulence of" exact="infectious diseases" post="[22â€&quot;24]. Among the factors contributing to immunosenescence is the"/>
  <result pre="diseases [22â€&quot;24]. Among the factors contributing to immunosenescence is the" exact="chronic" post="involution of the thymus gland with increased age. Indeed,"/>
  <result pre="involution of the thymus gland with increased age. Indeed, the" exact="infection" post="rates of COVID-19, separated by age, are correlated with"/>
  <result pre="Figure 2 illustrates the hypothesised reciprocal relationship between immunosenescence and" exact="infectious disease" post="acquisition. In this model, age-associated immunosenescence leads to a"/>
  <result pre="2 illustrates the hypothesised reciprocal relationship between immunosenescence and infectious" exact="disease" post="acquisition. In this model, age-associated immunosenescence leads to a"/>
  <result pre="immunosenescence leads to a reduced ability to resist infection, while" exact="infection" post="produces biological damage and loss of homeostasis. This ultimately"/>
  <result pre="diseases, and further accelerates immunosenescence. In support of this model," exact="infections" post="and other age-related diseases are among the main causes"/>
  <result pre="where age-associated immunosenescence leads to reduced ability to resist infection;" exact="infection" post="leads to increased damage, loss of homeostasis, and accelerated"/>
  <result pre="which in turn leads to age-related diseases, further accelerating immunosenescence." exact="Infections" post="and other age-related diseases are among the main causes"/>
  <result pre="the classical preventative measures and treatment strategies used for targeting" exact="infectious diseases" post="may not be as effective, and there is a"/>
  <result pre="be used in isolation or as adjuvant therapies to reduce" exact="infection" post="risk, symptom severity, or improve vaccine efficacy. Vaccines Vaccine"/>
  <result pre="development is one of the most successful approaches for combating" exact="viral" post="diseases globally, and is often regarded as one of"/>
  <result pre="depends on the similarity of the vaccine strain with the" exact="viral" post="pathogenic strain in question. In addition, an individualâ€™s immune"/>
  <result pre="should exposure occur. Our current strategy for targeting annual influenza" exact="viral" post="outbreaks focuses on effective vaccination based on predictions of"/>
  <result pre="predictions of strain variants. People &amp;gt;60 years of age with" exact="chronic" post="medical conditions, such as type 2 diabetes or cardiovascular"/>
  <result pre="&amp;gt;60 years of age with chronic medical conditions, such as" exact="type 2" post="diabetes or cardiovascular disease, direct immunosuppression from HIV, post-transplant"/>
  <result pre="of age with chronic medical conditions, such as type 2" exact="diabetes" post="or cardiovascular disease, direct immunosuppression from HIV, post-transplant or"/>
  <result pre="with chronic medical conditions, such as type 2 diabetes or" exact="cardiovascular disease," post="direct immunosuppression from HIV, post-transplant or biologic treatment, pregnant"/>
  <result pre="BMI&amp;gt;40, are believed to be at higher risk for influenza" exact="infection" post="due to a weakened immune response [31]. Similarly, vaccines"/>
  <result pre="a weakened immune response [31]. Similarly, vaccines do not provide" exact="complete" post="protection in older populations due to age-related declines in"/>
  <result pre="vaccines may be the best preventative strategy for reducing the" exact="infection" post="rates, severity, and lethality of COVID-19, the rates to"/>
  <result pre="the rates to vaccines in the elderly will likely be" exact="lower" post="[35] and vaccine potentiation strategies [36] may be explored"/>
  <result pre="exposure to the virus is an alternative preventative strategy against" exact="viral" post="disease [31]. For influenza, the neuraminidase inhibitors oseltamivir and"/>
  <result pre="to the virus is an alternative preventative strategy against viral" exact="disease" post="[31]. For influenza, the neuraminidase inhibitors oseltamivir and zanamivir"/>
  <result pre="effects; for example, zanamivir can induce bronchospasms in patients with" exact="chronic" post="respiratory disease and asthma. Pharmacotherapy for individuals with infection"/>
  <result pre="for example, zanamivir can induce bronchospasms in patients with chronic" exact="respiratory" post="disease and asthma. Pharmacotherapy for individuals with infection remains"/>
  <result pre="example, zanamivir can induce bronchospasms in patients with chronic respiratory" exact="disease" post="and asthma. Pharmacotherapy for individuals with infection remains the"/>
  <result pre="with chronic respiratory disease and asthma. Pharmacotherapy for individuals with" exact="infection" post="remains the cornerstone of clinical practice. The success of"/>
  <result pre="new, direct-acting antiviral drugs that offer a potential cure for" exact="hepatitis C" post="[38]; to the highly active antiretroviral drugs that enable"/>
  <result pre="healthy life expectancy while on treatment; to antiviral drugs for" exact="herpes" post="simplex types 1 and 2 that lead to symptom"/>
  <result pre="expectancy while on treatment; to antiviral drugs for herpes simplex" exact="types 1 and 2" post="that lead to symptom alleviation but do not eradicate"/>
  <result pre="According to the recent COVID-19 treatment guidelines in China [43]," exact="symptomatic" post="treatment for COVID-19 patients is recommended for mild cases"/>
  <result pre="for superinfections, oxygen supplementation, non-invasive ventilation with or without positive" exact="pulmonary" post="pressure, and in some cases intubation and mechanical ventilation."/>
  <result pre="some cases intubation and mechanical ventilation. Although the projected global" exact="infection" post="rates are variable, we share a common concern that"/>
  <result pre="number of beds for hospitalization and ventilation units if the" exact="disease" post="spread does not slow down. COVID-19 rehabilitation Even asymptomatic"/>
  <result pre="spread does not slow down. COVID-19 rehabilitation Even asymptomatic COVID-19" exact="infections" post="can induce lung fibrosis, which may lead to reduced"/>
  <result pre="slow down. COVID-19 rehabilitation Even asymptomatic COVID-19 infections can induce" exact="lung fibrosis," post="which may lead to reduced function of the respiratory"/>
  <result pre="lung fibrosis, which may lead to reduced function of the" exact="respiratory" post="system. Further, severe cases are often complicated by bacterial"/>
  <result pre="the respiratory system. Further, severe cases are often complicated by" exact="bacterial infections" post="and pneumonia, leading to fibrosis. Therefore, COVID-19 rehabilitation may"/>
  <result pre="respiratory system. Further, severe cases are often complicated by bacterial" exact="infections" post="and pneumonia, leading to fibrosis. Therefore, COVID-19 rehabilitation may"/>
  <result pre="regenerative medicine therapies. Geroprotective and senoremediative strategies for COVID-19 gerolavic" exact="infection" post="There are multiple interventions proposed in the academic literature"/>
  <result pre="proposed in the academic literature to remedy age-associated increases in" exact="infection" post="rates, severity, and lethality for a variety of infections."/>
  <result pre="backed by promising clinical evidence of improved immune response to" exact="viral infection" post="in the elderly, although still limited by a lack"/>
  <result pre="by promising clinical evidence of improved immune response to viral" exact="infection" post="in the elderly, although still limited by a lack"/>
  <result pre="immune response to viral infection in the elderly, although still" exact="limited" post="by a lack of large clinical trials, are sirolimus"/>
  <result pre="response to conventional prevention and treatment strategies, prevent infection, reduce" exact="disease" post="severity and lethality, and may also increase longevity. Rapamycin"/>
  <result pre="such as boosting T cell responses in reaction to pathogen" exact="infection" post="and vaccination [74]. Nevertheless, this would not be the"/>
  <result pre="physiological paradox in clinical medicine. The administration of beta-blockers to" exact="heart" post="failure patients at first seemed contradictory, as these compounds"/>
  <result pre="proved to provide the most benefit for the treatment of" exact="heart" post="failure patients. Likewise, hormonal treatment of hormone-dependent cancers, such"/>
  <result pre="patients. Likewise, hormonal treatment of hormone-dependent cancers, such as testosterone-dependent" exact="prostate cancer," post="seems incongruous. However, administration of a synthetic version of"/>
  <result pre="risks; indeed, there is some indication that morbidity from coronavirus" exact="infections" post="occurs from secondary overactive immune responses [75, 76]. In"/>
  <result pre="is some indication that morbidity from coronavirus infections occurs from" exact="secondary" post="overactive immune responses [75, 76]. In addition to rapamycin,"/>
  <result pre="explore clinical applications of these compounds in human clinical trials." exact="Multiple" post="clinical observations suggested that patients with cytomegalovirus (CMV) disease"/>
  <result pre="trials. Multiple clinical observations suggested that patients with cytomegalovirus (CMV)" exact="disease" post="who were treated with rapamycin demonstrated better outcomes and"/>
  <result pre="rapamycin on the CD8+ memory T cell response following pathogen" exact="infection" post="[74, 80]. Later studies also showed that monkeys treated"/>
  <result pre="enhanced differentiation of memory T cells following vaccination with Modified" exact="Vaccinia" post="Ankara [81]. Additional clinical studies by Mannick et al."/>
  <result pre="tolerated [82]. Further studies demonstrated enhanced immune function and reduced" exact="infection" post="in elderly patients receiving tolerable doses of everolimus. Mannick"/>
  <result pre="with a significant (P=0.001) decrease in the rate of reported" exact="infections" post="[83]. Mannick and colleagues further conducted a phase 2a"/>
  <result pre="with a significant (P=0.001) decrease in the rate of reported" exact="infections" post="[83]. A follow-up trial of dactolisib alone (BEZ235 rebranded"/>
  <result pre="of dactolisib alone (BEZ235 rebranded as RTB101) for prevention of" exact="respiratory" post="tract infections in the elderly did not meet the"/>
  <result pre="alone (BEZ235 rebranded as RTB101) for prevention of respiratory tract" exact="infections" post="in the elderly did not meet the primary endpoint"/>
  <result pre="respiratory tract infections in the elderly did not meet the" exact="primary" post="endpoint and further trials were withdrawn [85]. In prior"/>
  <result pre="gerolavic infections. Metformin Metformin is a drug approved to treat" exact="type 2" post="diabetes but appears to target a number of aging-related"/>
  <result pre="Metformin Metformin is a drug approved to treat type 2" exact="diabetes" post="but appears to target a number of aging-related mechanisms,"/>
  <result pre="to a new occurrence of a composite outcome that includes" exact="cardiovascular" post="events, cancer, dementia, and mortality [87]. Metformin would likely"/>
  <result pre="would likely still be contraindicated in elderly patients with advanced" exact="chronic" post="kidney disease and eGFR&amp;lt;15. A reduced dose would potentially"/>
  <result pre="likely still be contraindicated in elderly patients with advanced chronic" exact="kidney disease" post="and eGFR&amp;lt;15. A reduced dose would potentially be required"/>
  <result pre="still be contraindicated in elderly patients with advanced chronic kidney" exact="disease" post="and eGFR&amp;lt;15. A reduced dose would potentially be required"/>
  <result pre="potentially be required for eGFR&amp;lt;30 due to a risk of" exact="lactic acidosis." post="The effects on gerophilic and gerolavic infections should be"/>
  <result pre="risk of lactic acidosis. The effects on gerophilic and gerolavic" exact="infections" post="should be carefully examined in the context of the"/>
  <result pre="NAPRT, NMNAT, and NADS. Large-scale trials of nicotinic acid for" exact="cardiovascular disease" post="[94, 95] showed some efficacy, but produced adverse side"/>
  <result pre="NMNAT, and NADS. Large-scale trials of nicotinic acid for cardiovascular" exact="disease" post="[94, 95] showed some efficacy, but produced adverse side"/>
  <result pre="gerolavic infections, as the underlying biology of NAS metabolism and" exact="viral" post="infections is still poorly understood. Recent studies in humans"/>
  <result pre="infections, as the underlying biology of NAS metabolism and viral" exact="infections" post="is still poorly understood. Recent studies in humans demonstrate"/>
  <result pre="depletion and thus initiate or perpetuate an increase in sterile" exact="chronic" post="inflammation. Many drug classes, ranging from fibrates to cardiac"/>
  <result pre="data suggest that flavonoids may be used for prophylaxis in" exact="upper" post="respiratory tract infections [105]. Although senolytic drugs would have"/>
  <result pre="suggest that flavonoids may be used for prophylaxis in upper" exact="respiratory" post="tract infections [105]. Although senolytic drugs would have a"/>
  <result pre="flavonoids may be used for prophylaxis in upper respiratory tract" exact="infections" post="[105]. Although senolytic drugs would have a scientifically plausible"/>
  <result pre="been shown that these classes of drugs would protect against" exact="infection" post="or could be used as adjuncts to vaccination. In"/>
  <result pre="tissue, and could thus deplete beneficial protective stem cell reserves." exact="Intermittent" post="caloric restriction It has been shown in multiple studies"/>
  <result pre="been explored in clinical trials as an adjuvant therapy for" exact="cancer" post="treatments [107]. Within 8-12 hours of food restriction, ketones"/>
  <result pre="Treg cells and peripherally-derived Treg (pTreg) cells. Thus, inducing a" exact="peripheral" post="Treg response in older individuals might be a feasible"/>
  <result pre="against the disease. Major global antiviral strategy to prevent new" exact="infective" post="cases and fight epidemics. Viral illnesses eradicated/controlled due to"/>
  <result pre="antiviral strategy to prevent new infective cases and fight epidemics." exact="Viral" post="illnesses eradicated/controlled due to previous successful vaccination programs. Vaccinated"/>
  <result pre="previous successful vaccination programs. Vaccinated people do not develop an" exact="infection" post="or develop a milder infection. Reduces the number of"/>
  <result pre="significantly reduced due to immunosenescence and multimorbidity.Possible immunogenicity and mild" exact="viral" post="prodrome symptoms as a result of vaccination. Targeted Antibodies"/>
  <result pre="recovered individuals.Antibodies targeting specific SARS-CoV-2 proteins. Successfully trialed in other" exact="viral" post="diseases including Ebola. Reduction in disease severity and lethality"/>
  <result pre="Successfully trialed in other viral diseases including Ebola. Reduction in" exact="disease" post="severity and lethality in exposed individuals. Risk of systemic"/>
  <result pre="in disease severity and lethality in exposed individuals. Risk of" exact="systemic" post="immune reactions and certain blood borne infections. Targeted Small"/>
  <result pre="certain blood borne infections. Targeted Small Molecule Drugs for SARS-CoV-2" exact="Selective" post="small molecule inhibitors targeting SARS-CoV-2 proteins such as 3C-like"/>
  <result pre="small molecule inhibitors targeting SARS-CoV-2 proteins such as 3C-like protease." exact="Multiple" post="examples from Influenza. Neuraminidase and endonuclease inhibitors. Reduction in"/>
  <result pre="Multiple examples from Influenza. Neuraminidase and endonuclease inhibitors. Reduction in" exact="disease" post="duration, severity, and lethality in exposed individuals. Mild side"/>
  <result pre="etc. Symptomatic Treatments Non-steroidal anti-inflammatory drugs (NSAIDs), antibacterials, pain management." exact="Multiple" post="clinical trials, common use. Reduction in severity of disease."/>
  <result pre="that might increase the probability of increased longevity. Risk of" exact="pancytopenia" post="and potentially fatal infection risk.Risk of nephrotoxicity although milder"/>
  <result pre="probability of increased longevity. Risk of pancytopenia and potentially fatal" exact="infection" post="risk.Risk of nephrotoxicity although milder side effect profile reported"/>
  <result pre="hepatic gluconeogenesis. Long-term use in humans. 1st line treatment for" exact="type 2" post="diabetes, leading to weight loss and improved glucose metabolism."/>
  <result pre="glucose metabolism. Improved fertility in polycystic ovarian syndrome. Reduction in" exact="cardiovascular" post="events, cancer, dementia, and mortality. Diarrhea in 20% of"/>
  <result pre="ovarian syndrome. Reduction in cardiovascular events, cancer, dementia, and mortality." exact="Diarrhea" post="in 20% of patients.Contraindicated in patients with eGFR &amp;lt;15"/>
  <result pre="reduced dose required if eGFR &amp;lt;30 due to risk of" exact="lactic acidosis." post="NAD Boosters Sirtuin Activation.PARP efficacy augmentation. Improvement in cellular"/>
  <result pre="blood pressure.Improvement in exercise capacity. Reduction in immunosenescence, thus reduced" exact="infection" post="risk and improved vaccine response. Improved endothelial function and"/>
  <result pre="risk and improved vaccine response. Improved endothelial function and reduced" exact="cardiovascular disease" post="risk, potential increased lifespan. No increase in cellular NAD"/>
  <result pre="and improved vaccine response. Improved endothelial function and reduced cardiovascular" exact="disease" post="risk, potential increased lifespan. No increase in cellular NAD"/>
  <result pre="circulating inflammatory cytokines. Senolytics Reduction in anti-apoptotic senescent inactive cells." exact="Multiple" post="drug classes mentioned with varying disease mechanisms. Reduced adipose"/>
  <result pre="anti-apoptotic senescent inactive cells. Multiple drug classes mentioned with varying" exact="disease" post="mechanisms. Reduced adipose tissue senescent cell burden in a"/>
  <result pre="inactive cells. Multiple drug classes mentioned with varying disease mechanisms." exact="Reduced" post="adipose tissue senescent cell burden in a short human"/>
  <result pre="disease mechanisms. Reduced adipose tissue senescent cell burden in a" exact="short" post="human trial.Improvement in pulmonary fibrosis treatment. Reduction in senescent"/>
  <result pre="tissue senescent cell burden in a short human trial.Improvement in" exact="pulmonary" post="fibrosis treatment. Reduction in senescent cell burden and thus"/>
  <result pre="pulmonary fibrosis treatment. Reduction in senescent cell burden and thus" exact="chronic" post="sterile inflammation; reduction of chronic disease burden. Removal of"/>
  <result pre="senescent cell burden and thus chronic sterile inflammation; reduction of" exact="chronic" post="disease burden. Removal of quiescent stem cells and depletion"/>
  <result pre="cell burden and thus chronic sterile inflammation; reduction of chronic" exact="disease" post="burden. Removal of quiescent stem cells and depletion of"/>
  <result pre="to cardiovascular, kidney, liver, and CNS damage. Caloric Restriction and" exact="Intermittent" post="Fasting Promotion of autophagy, metabolic flexibility.Increase in beta hydroxybutyrate."/>
  <result pre="reduction in body weight, improvement of insulin resistance, thus reduced" exact="cardiovascular" post="risks and certain cancer type risks. Sarcopenia, osteoporosis. Risk"/>
  <result pre="improvement of insulin resistance, thus reduced cardiovascular risks and certain" exact="cancer" post="type risks. Sarcopenia, osteoporosis. Risk of nutritional deficiencies and"/>
  <result pre="humans with GH deficiency.Improvement in anabolic function and increase in" exact="muscle" post="mass. Prevention of thymus degeneration and increase in immune"/>
  <result pre="and increase in immune function. Improved mood and body composition." exact="Increased" post="cancer risk. Type 2 diabetes. Connective tissue proliferation. FOXP3+"/>
  <result pre="increase in immune function. Improved mood and body composition. Increased" exact="cancer" post="risk. Type 2 diabetes. Connective tissue proliferation. FOXP3+ activation"/>
  <result pre="immune function. Improved mood and body composition. Increased cancer risk." exact="Type 2" post="diabetes. Connective tissue proliferation. FOXP3+ activation One of the"/>
  <result pre="mood and body composition. Increased cancer risk. Type 2 diabetes." exact="Connective" post="tissue proliferation. FOXP3+ activation One of the key mediators"/>
  <result pre="geroprotectors as a preventative measure before patients are exposed to" exact="disease" post="(Figure 4). In the case of COVID-19 as the"/>
  <result pre="COVID-19 as the number of cases worldwide increases, meta-analysis of" exact="infection" post="rates, severity, and lethality should be performed rapidly to"/>
  <result pre="administration of geroprotectors for prevention, treatment and rehabilitation of gerolavic" exact="respiratory" post="diseases. As COVID-19 causes substantial lung damage, antifibrotics, senolytics"/>
  <result pre="to assist in patient recovery to prevent a reduction in" exact="respiratory" post="function. Using biological aging clocks as markers of immunosenescence"/>
  <result pre="and anti-aging interventions intended to ameliorate the population-level effects of" exact="infectious diseases" post="during flu seasons and pandemics. We call for rigorous"/>
  <result pre="interventions described herein. DISCUSSION SARS-CoV-2 is a betacoronavirus that causes" exact="respiratory" post="illness, and is genetically most similar to SARS-CoV, the"/>
  <result pre="that caused the SARS epidemic of 2003. The Middle East" exact="respiratory" post="syndrome (MERS) epidemic was also caused by a betacoronavirus"/>
  <result pre="caused the SARS epidemic of 2003. The Middle East respiratory" exact="syndrome" post="(MERS) epidemic was also caused by a betacoronavirus that"/>
  <result pre="epidemic was also caused by a betacoronavirus that induces severe" exact="respiratory" post="illness. Both SARS and MERS were contained before they"/>
  <result pre="cost tens or even hundreds of millions of dollars [122]." exact="Multiple" post="biotechnology companies are in the same situation and will"/>
  <result pre="targeting age-associated pathologies and immunosenescence, which could decrease the comorbidity," exact="infection" post="rates, severity, and lethality of the disease, will remain"/>
  <result pre="will remain commercially-viable even when the pandemic subsides. In addition," exact="respiratory" post="infections are now the third leading cause of death"/>
  <result pre="remain commercially-viable even when the pandemic subsides. In addition, respiratory" exact="infections" post="are now the third leading cause of death in"/>
  <result pre="the third leading cause of death in the world, following" exact="cardiac disease" post="and stroke [123], further justifying the need for these"/>
  <result pre="third leading cause of death in the world, following cardiac" exact="disease" post="and stroke [123], further justifying the need for these"/>
  <result pre="cause of death in the world, following cardiac disease and" exact="stroke" post="[123], further justifying the need for these interventions. Considering"/>
  <result pre="countries will find it challenging to cope with the increased" exact="disease" post="burden and hospital needs. Conventional approaches to prevention such"/>
  <result pre="vaccines are much needed, but even these do not offer" exact="complete" post="protection in the elderly due to multi-morbidity and age-related"/>
  <result pre="to newly developed vaccines are necessary to help eradicate the" exact="disease" post="and reduce the associated mortality. To avoid substantial loss"/>
  <result pre="rapalogs, can induce immunopotentiation, increase resistance to infection, and reduce" exact="disease" post="severity in the elderly, without severe side effects. Serendipitously,"/>
  <result pre="melatonin and sirolimus (rapamycin) in combination to treat the COVID-19" exact="infection" post="outside the context of geroprotection [124]. Many of these"/>
  <result pre="harmful to the elderly after infection, and may actually increase" exact="disease" post="severity and lethality. However, it may be possible to"/>
  <result pre="growing COVID-19 pandemic, researchers have united globally to tackle a" exact="disease" post="that is impacting lives and healthcare systems around the"/>
  <result pre="that COVID-19 has a gerophilic and gerolavic profile, being more" exact="infectious" post="and more severe in the elderly. In this paper,"/>
  <result pre="prevention or treatment. Furthermore, this perspective is based on the" exact="limited" post="data from the first weeks of the COVID-19 outbreak."/>
  <result pre="being delivered to the community amidst exceptional coverage of this" exact="disease" post="in the media at present. ACKNOWLEDGMENTS The author would"/>
  <result pre="and comments on the new term â€œgerolavicâ€� to describe the" exact="infections" post="harmful to the elderly, which did not previously exist;"/>
  <result pre="senescence.Science. 2019; 366:576â€&quot;78. 10.1126/science.aay731931672885 4ZhavoronkovA, BhullarB. Classifying aging as a" exact="disease" post="in the context of ICD-11.Front Genet. 2015; 6:326. 10.3389/fgene.2015.0032626583032"/>
  <result pre="Aging, frailty and age-related diseases.Biogerontology. 2010; 11:547â€&quot;63. 10.1007/s10522-010-9287-220559726 7KlineKA, BowdishDM." exact="Infection" post="in an aging population.Curr Opin Microbiol. 2016; 29:63â€&quot;67. 10.1016/j.mib.2015.11.00326673958"/>
  <result pre="Opin Microbiol. 2016; 29:63â€&quot;67. 10.1016/j.mib.2015.11.00326673958 8BrunnerS, Herndler-BrandstetterD, WeinbergerB, Grubeck-LoebensteinB. Persistent" exact="viral" post="infections and immune aging.Ageing Res Rev. 2011; 10:362â€&quot;69. 10.1016/j.arr.2010.08.00320727987"/>
  <result pre="Microbiol. 2016; 29:63â€&quot;67. 10.1016/j.mib.2015.11.00326673958 8BrunnerS, Herndler-BrandstetterD, WeinbergerB, Grubeck-LoebensteinB. Persistent viral" exact="infections" post="and immune aging.Ageing Res Rev. 2011; 10:362â€&quot;69. 10.1016/j.arr.2010.08.00320727987 9MeyerKC."/>
  <result pre="and immune aging.Ageing Res Rev. 2011; 10:362â€&quot;69. 10.1016/j.arr.2010.08.00320727987 9MeyerKC. Lung" exact="infections" post="and aging.Ageing Res Rev. 2004; 3:55â€&quot;67. 10.1016/j.arr.2003.07.00215163102 10YoshikawaTT. Epidemiology"/>
  <result pre="3:55â€&quot;67. 10.1016/j.arr.2003.07.00215163102 10YoshikawaTT. Epidemiology and unique aspects of aging and" exact="infectious" post="diseases.Clin Infect Dis. 2000; 30:931â€&quot;33. 10.1086/31379210880303 11TianS, HuN, LouJ,"/>
  <result pre="LiuN, LiuD, ChenG, ZhangY, LiD, et al.. Characteristics of COVID-19" exact="infection" post="in Beijing.J Infect. 2020; 80:401â€&quot;06. 10.1016/j.jinf.2020.02.01832112886 12TeamTNCPERE. The Epidemiological"/>
  <result pre="The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus" exact="Diseases" post="(COVID-19).2020; 2:113â€&quot;122. 13collab: Worldometer. COVID-19 Coronavirus Outbreak.https://www.worldometers.info/coronavirus/ 14LevittM. Analysis"/>
  <result pre="The Lancet.https://www.thelancet.com/gbd 18collab: Actuarial Life Table. https://www.ssa.gov/oact/STATS/table4c6.html 19collab: Centers for" exact="Disease" post="Control. Estimated Influenza Illnesses, Medical visits, Hospitalizations, and Deaths"/>
  <result pre="Medical Treatment Expert Group for Covid-19*. Clinical Characteristics of Coronavirus" exact="Disease" post="2019 in China.N Engl J Med. 202010.1056/NEJMoa2002032 21GruverAL, HudsonLL,"/>
  <result pre="Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases.ACS" exact="Central" post="Science. 202010.1021/acscentsci.0c00272 25FloresKG, LiJ, SempowskiGD, HaynesBF, HaleLP. Analysis of"/>
  <result pre="â€œCoronavirus Infectionsâ€� - List Results - ClinicalTrials.gov.https://clinicaltrials.gov/search/open/condition=%22Coronavirus+Infections%22 31collab: Centers for" exact="Disease" post="Control andPrevention.. Influenza Antiviral Medications: Clinician Summary. 2020https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm 32MontoAS,"/>
  <result pre="10.1046/j.1532-5415.2001.49204.x11555062 38LiDK, ChungRT. Overview of Direct-Acting Antiviral Drugs and Drug" exact="Resistance" post="of Hepatitis C Virus.Methods Mol Biol. 2019; 1911:3â€&quot;32. 10.1007/978-1-4939-8976-8_130593615"/>
  <result pre="ChungRT. Overview of Direct-Acting Antiviral Drugs and Drug Resistance of" exact="Hepatitis" post="C Virus.Methods Mol Biol. 2019; 1911:3â€&quot;32. 10.1007/978-1-4939-8976-8_130593615 39JeffersonT, JonesM,"/>
  <result pre="BlagosklonnyMV. Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred" exact="female" post="mice.Cell Cycle. 2011; 10:4230â€&quot;36. 10.4161/cc.10.24.1848622107964 62WilkinsonJE, BurmeisterL, BrooksSV, ChanCC,"/>
  <result pre="HofbauerGF, et al., and collab: TUMORAPA Study Group. Sirolimus and" exact="secondary" post="skin-cancer prevention in kidney transplantation.N Engl J Med. 2012;"/>
  <result pre="Sirolimus therapy after early cyclosporine withdrawal reduces the risk for" exact="cancer" post="in adult renal transplantation.J Am Soc Nephrol. 2006; 17:581â€&quot;89."/>
  <result pre="after early cyclosporine withdrawal reduces the risk for cancer in" exact="adult" post="renal transplantation.J Am Soc Nephrol. 2006; 17:581â€&quot;89. 10.1681/ASN.200509099316434506 68BlagosklonnyMV."/>
  <result pre="age-related diseases.Aging (Albany NY). 2009; 1:281â€&quot;88. 10.18632/aging.10003420157517 70BlagosklonnyMV. Prevention of" exact="cancer" post="by inhibiting aging.Cancer Biol Ther. 2008; 7:1520â€&quot;24. 10.4161/cbt.7.10.666318769112 71BlagosklonnyMV."/>
  <result pre="73BakS, TischerS, DragonA, RavensS, PapeL, KoeneckeC, OelkeM, BlasczykR, Maecker-KolhoffB, Eiz-VesperB." exact="Selective" post="Effects of mTOR Inhibitor Sirolimus on NaÃ¯ve and CMV-Specific"/>
  <result pre="immunobiology in transplantation.Am J Transplant. 2011; 11:654â€&quot;59. 10.1111/j.1600-6143.2011.03473.x21446969 75GarcÃ­a-SastreA, BironCA." exact="Type 1" post="interferons and the virus-host relationship: a lesson in dÃ©tente.Science."/>
  <result pre="2015; 6:23238â€&quot;48. 10.18632/oncotarget.483626177051 80OzakiKS, CÃ¢maraNO, GalanteNZ, CamargoLF, Pacheco-SilvaA. Decreased Cytomegalovirus" exact="infection" post="after antilymphocyte therapy in sirolimus-treated renal transplant patients.Int Immunopharmacol."/>
  <result pre="the magnitude and quality of viral-specific CD8+ T-cell responses to" exact="vaccinia" post="virus vaccination in rhesus macaques.Am J Transplant. 2011; 11:613â€&quot;18."/>
  <result pre="QuinnD, GlassDJ, KlicksteinLB. TORC1 inhibition enhances immune function and reduces" exact="infections" post="in the elderly.Sci Transl Med. 2018; 10. 10.1126/scitranslmed.aaq156429997249 84LiuTJ,"/>
  <result pre="of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.Mol" exact="Cancer" post="Ther. 2009; 8:2204â€&quot;10. 10.1158/1535-7163.MCT-09-016019671762 85collab: ClinicalTrials.gov. Effect of RTB101"/>
  <result pre="10.1158/1535-7163.MCT-09-016019671762 85collab: ClinicalTrials.gov. Effect of RTB101 on Illness Associated With" exact="Respiratory" post="Tract Infections in the Elderly.Nat Biotechnol. 2020https://clinicaltrials.gov/ct2/show/NCT04139915 86collab: ClinicalTrials.gov."/>
  <result pre="85collab: ClinicalTrials.gov. Effect of RTB101 on Illness Associated With Respiratory" exact="Tract" post="Infections in the Elderly.Nat Biotechnol. 2020https://clinicaltrials.gov/ct2/show/NCT04139915 86collab: ClinicalTrials.gov. Search"/>
  <result pre="ClinicalTrials.gov. Effect of RTB101 on Illness Associated With Respiratory Tract" exact="Infections" post="in the Elderly.Nat Biotechnol. 2020https://clinicaltrials.gov/ct2/show/NCT04139915 86collab: ClinicalTrials.gov. Search of:"/>
  <result pre="(NMN) on Cardiometabolic Function.https://clinicaltrials.gov/ct2/show/results/NCT03432871 89collab: ClinicalTrials.gov.Effects of Nicotinamide Riboside on" exact="Metabolism" post="and Vascular Function.https://clinicaltrials.gov/ct2/show/NCT03501433 90collab: ClinicalTrials.gov.Nicotinamide Riboside and Metabolic Health.https://clinicaltrials.gov/ct2/show/NCT02835664"/>
  <result pre="Cardiometabolic Function.https://clinicaltrials.gov/ct2/show/results/NCT03432871 89collab: ClinicalTrials.gov.Effects of Nicotinamide Riboside on Metabolism and" exact="Vascular" post="Function.https://clinicaltrials.gov/ct2/show/NCT03501433 90collab: ClinicalTrials.gov.Nicotinamide Riboside and Metabolic Health.https://clinicaltrials.gov/ct2/show/NCT02835664 91collab: ClinicalTrials.gov.Nicotinamide"/>
  <result pre="90collab: ClinicalTrials.gov.Nicotinamide Riboside and Metabolic Health.https://clinicaltrials.gov/ct2/show/NCT02835664 91collab: ClinicalTrials.gov.Nicotinamide Riboside in" exact="Systolic" post="Heart Failure.https://clinicaltrials.gov/ct2/show/NCT03423342 92DolopikouCF, KourtzidisIA, MargaritelisNV, VrabasIS, KoidouI, KyparosA, TheodorouAA,"/>
  <result pre="ClinicalTrials.gov.Nicotinamide Riboside and Metabolic Health.https://clinicaltrials.gov/ct2/show/NCT02835664 91collab: ClinicalTrials.gov.Nicotinamide Riboside in Systolic" exact="Heart" post="Failure.https://clinicaltrials.gov/ct2/show/NCT03423342 92DolopikouCF, KourtzidisIA, MargaritelisNV, VrabasIS, KoidouI, KyparosA, TheodorouAA, PaschalisV,"/>
  <result pre="Failure.https://clinicaltrials.gov/ct2/show/NCT03423342 92DolopikouCF, KourtzidisIA, MargaritelisNV, VrabasIS, KoidouI, KyparosA, TheodorouAA, PaschalisV, NikolaidisMG." exact="Acute" post="nicotinamide riboside supplementation improves redox homeostasis and exercise performance"/>
  <result pre="59:505â€&quot;15. 10.1007/s00394-019-01919-430725213 93MartensCR, DenmanBA, MazzoMR, ArmstrongML, ReisdorphN, McQueenMB, ChoncholM, SealsDR." exact="Chronic" post="nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in"/>
  <result pre="AIM-HIGH.https://clinicaltrials.gov/ct2/show/NCT00880178 95collab: ClinicalTrials.gov.Treatment of HDL to Reduce the Incidence of" exact="Vascular" post="Events HPS2-THRIVE.https://clinicaltrials.gov/ct2/show/NCT00461630 96MendelsohnAR, LarrickJW. Interacting NAD+ and Cell Senescence"/>
  <result pre="AkermanI, et al.. Nicotinamide Riboside Augments the Aged Human Skeletal" exact="Muscle" post="NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures.Cell Rep."/>
  <result pre="Nicotinamide Mononucleotide (NMN) and 6 Weeks of Exercise in Obese" exact="Female" post="Mice.Front Pharmacol. 2016; 7:258. 10.3389/fphar.2016.0025827594836 100BussoN, KarababaM, NobileM, RolazA,"/>
  <result pre="CD38 Is Robustly Induced in Human Macrophages and Monocytes in" exact="Inflammatory" post="Conditions.Front Immunol. 2018; 9:1593. 10.3389/fimmu.2018.0159330042766 102KirklandJL, TchkoniaT, ZhuY, NiedernhoferLJ,"/>
  <result pre="GuihoR, WolterK, PomboJ, IrvineEE, InnesAJ, BirchJ, GlegolaJ, ManshaeiS, et al.." exact="Cardiac" post="glycosides are broad-spectrum senolytics.Nat Metab. 2019; 1:1074â€&quot;88. 10.1038/s42255-019-0122-z31799499 104HicksonLJ,"/>
  <result pre="47:446â€&quot;56. 10.1016/j.ebiom.2019.08.06931542391 105SomervilleVS, BraakhuisAJ, HopkinsWG. Effect of Flavonoids on Upper" exact="Respiratory" post="Tract Infections and Immune Function: A Systematic Review and"/>
  <result pre="10.1016/j.ebiom.2019.08.06931542391 105SomervilleVS, BraakhuisAJ, HopkinsWG. Effect of Flavonoids on Upper Respiratory" exact="Tract" post="Infections and Immune Function: A Systematic Review and Meta-Analysis.Adv"/>
  <result pre="105SomervilleVS, BraakhuisAJ, HopkinsWG. Effect of Flavonoids on Upper Respiratory Tract" exact="Infections" post="and Immune Function: A Systematic Review and Meta-Analysis.Adv Nutr."/>
  <result pre="exploratory outcomes of a multicentre, phase 2, randomised controlled trial.Lancet" exact="Diabetes" post="Endocrinol. 2019; 7:673â€&quot;83. 10.1016/S2213-8587(19)30151-231303390 107TemplemanI, GonzalezJT, ThompsonD, BettsJA. The"/>
  <result pre="Nutr Soc. 2020; 79:76â€&quot;87. 10.1017/S002966511900063631023390 108de CaboR, MattsonMP. Effects of" exact="Intermittent" post="Fasting on Health, Aging, and Disease.N Engl J Med."/>
  <result pre="Inhibition of HDAC9 increases T regulatory cell function and prevents" exact="colitis" post="in mice.Gastroenterology. 2010; 138:583â€&quot;94. 10.1053/j.gastro.2009.10.03719879272 111BeierUH, WangL, BhattiTR, LiuY,"/>
  <result pre="VolosnikovaM, OzerovIV, PutinE, SkibinaE, CorteseF, ZhavoronkovA. Machine Learning on Human" exact="Muscle" post="Transcriptomic Data for Biomarker Discovery and Tissue-Specific Drug Target"/>
  <result pre="Sci. 2019; 40:546â€&quot;49. 10.1016/j.tips.2019.05.00431279569 119collab: UK National Health Service.SARS (severe" exact="acute" post="respiratory syndrome).https://www.nhs.uk/conditions/sars/ 120collab: Insilico Medicine.Insilico Medicine publishes molecular structures"/>
  <result pre="2019; 40:546â€&quot;49. 10.1016/j.tips.2019.05.00431279569 119collab: UK National Health Service.SARS (severe acute" exact="respiratory" post="syndrome).https://www.nhs.uk/conditions/sars/ 120collab: Insilico Medicine.Insilico Medicine publishes molecular structures for"/>
  <result pre="industryâ€™s grand challenge.Nat Rev Drug Discov. 2010; 9:203â€&quot;14. 10.1038/nrd307820168317 123MayorS." exact="Acute" post="respiratory infections are worldâ€™s third leading cause of death.BMJ."/>
  <result pre="grand challenge.Nat Rev Drug Discov. 2010; 9:203â€&quot;14. 10.1038/nrd307820168317 123MayorS. Acute" exact="respiratory" post="infections are worldâ€™s third leading cause of death.BMJ. 2010;"/>
  <result pre="challenge.Nat Rev Drug Discov. 2010; 9:203â€&quot;14. 10.1038/nrd307820168317 123MayorS. Acute respiratory" exact="infections" post="are worldâ€™s third leading cause of death.BMJ. 2010; 341:c6360â€&quot;c6360."/>
 </snippets>
</snippetsTree>
